Geron (NASDAQ:GERN) Receives New Coverage from Analysts at Scotiabank

Equities researchers at Scotiabank started coverage on shares of Geron (NASDAQ:GERN) in a research note issued to investors on Wednesday, Marketbeat reports. The firm set a “sector outperform” rating and a $6.00 price target on the biopharmaceutical company’s stock. Scotiabank’s price target indicates a potential upside of 47.78% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on GERN. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Geron in a research report on Thursday, August 8th. StockNews.com upgraded Geron to a “sell” rating in a research report on Monday, August 5th. Leerink Partners assumed coverage on shares of Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target on the stock. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Geron in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Geron has a consensus rating of “Moderate Buy” and a consensus price target of $6.94.

Geron Stock Performance

Shares of GERN opened at $4.06 on Wednesday. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The company has a current ratio of 3.61, a quick ratio of 3.60 and a debt-to-equity ratio of 0.12. The company has a market cap of $2.41 billion, a PE ratio of -11.60 and a beta of 0.50. The stock has a 50-day moving average price of $4.45 and a 200-day moving average price of $4.23.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The business had revenue of $0.88 million during the quarter, compared to analyst estimates of $0.34 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. Geron’s revenue for the quarter was up 2941.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.09) earnings per share. As a group, equities analysts forecast that Geron will post -0.34 earnings per share for the current fiscal year.

Institutional Trading of Geron

Several large investors have recently modified their holdings of the business. National Bank of Canada FI lifted its holdings in Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 6,000 shares during the period. Crewe Advisors LLC lifted its stake in Geron by 870.0% in the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 8,700 shares during the period. Kingsview Wealth Management LLC bought a new stake in Geron in the first quarter valued at $34,000. American Trust purchased a new position in Geron during the 1st quarter valued at $38,000. Finally, Inspire Advisors LLC bought a new position in Geron in the 3rd quarter worth $68,000. 73.71% of the stock is owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.